Sage Journals: Discover world-class research

Abstract

Linear cutaneous lupus erythematosus is an unusual presentation of cutaneous lupus following Blaschko’s lines. It is described mostly in children and young adults and is usually not associated with systemic involvement. We report two cases of linear cutaneous lupus erythematosus in children who significantly improved after treatment with hydroxychloroquine in combination with topical corticosteroids and tacrolimus. These rare cases underline the importance of including linear cutaneous lupus erythematosus in the differential diagnosis of blaschkoid inflammatory lesions.

Keywords

Cutaneous lupus erythematosus linear lines of Blaschko pediatrics children

Introduction

In pediatrics, classification of cutaneous lupus erythematosus (CLE) is similar to adults, including acute CLE (ACLE), subacute CLE (SCLE), and chronic CLE (CCLE).^1,2 Childhood-onset CLE may, however, differ in demographics and disease progression. Median age at diagnosis varies between 11.7 and 14 years, with a female predominance of about 2F:1M,^1,2 except in pre-pubertal onset¹ and CCLE² where an equal sex distribution is observed. CCLE is most commonly reported (45%–60%), followed by ACLE (34%–35%).^1,2

Less commonly known, linear CLE (LCLE) is a rare presentation of CLE following Blaschko’s lines.³ This distinct subtype is described mostly in children and young adults. Herein, we report two rare cases of LCLE occurring during childhood.

Case report

Case 1

A 12-year-old girl presented to the Pediatric Dermatology Clinic for a 6-year history of asymptomatic linear plaques on her knee. She was not known for any diseases and didn’t take any medication. The patient had no systemic symptoms such as fever, weight loss, arthralgias, oral ulcers, photosensitivity, or cardiopulmonary symptoms. Atrophic, squamous, and erythemato-violaceous plaques following Blaschko’s lines were noted on her left knee (Figure 1). Antinuclear antibodies (ANA), extractable nuclear antigen (ENA) antibodies (full panel including anti-SSA, anti-SSB, anti-Sm, anti-RNP, anti-Scl-70, anti-Jo-1 and anti-CENP-B), and anti-double stranded DNA (anti-dsDNA) antibodies were negative. Laboratory tests such as complete blood count, creatinine, urinalysis, liver tests, and C-reactive protein were normal.

Figure 1.

Linear cutaneous lupus erythematosus with erythemato-violaceous and squamous papules and plaques with some atrophy along medial left knee.

Skin biopsy revealed vacuolar interface dermatitis with superficial and deep lymphohistiocytic perivascular and periadnexal infiltrates, lymphocytic vasculitis and increased dermal mucin deposition (Figure 2). Direct immunofluorescence (DIF) was not done. Little response was noted under betamethasone dipropionate 0.05% cream. Hydroxychloroquine (5 mg/kg/day) combined with tacrolimus 0.1% ointment led to a significant improvement within 6 months.

Figure 2.

A hematoxylin eosin saffron–stained section at 100× magnification shows vacuolar interface dermatitis, lymphohistiocytic perivascular and periadnexal infiltrates and lymphocytic vasculitis. Collagen bundles are separated by a clear substance within deep dermis.

Case 2

A healthy 15-year-old boy presented a 3-year history of slightly pruriginous linear lesions on his thigh. There were no systemic symptoms, and a review of systems was negative. Blaschkoid squamous and erythemato-violaceous papules with follicular plugging were observed on his left anterior and medial thigh (Figure 3). ANA, ENA full panel and anti-dsDNA were negative, and the remaining laboratory investigations were normal. Skin biopsy showed findings similar to the first patient (Figure 4). DIF was not done. Complete resolution was noted within 5 months under hydroxychloroquine (5 mg/kg/day) with clobetasol propionate 0.05% cream (for 5 weeks), followed by tacrolimus 0.1% ointment.

Figure 3.

Blaschkoid cutaneous lupus erythematosus: confluent squamous erythemato-violaceous papules with follicular plugging on left thigh.

Figure 4.

A hematoxylin eosin saffron–stained section at 100× magnification shows vacuolar interface dermatitis, lymphohistiocytic perivascular and periadnexal infiltrates, and lymphocytic vasculitis.

Discussion

LCLE represents a rare subtype of CLE mostly described among children and young adults.³ The term “linear” refers to its peculiar clinical presentation in which lesions follow Blaschko’s lines. The latter illustrate pathways of ectodermal development during embryogenesis and are subject to mosaicism, resulting in apparent distinction between genetically abnormal and normal skin.⁴ With keratinocyte apoptosis known as a key event for initiating CLE, it is hypothesized that genetically altered keratinocytes in LCLE may involve apoptotic pathways, hence predisposing them to apoptosis induced by ultraviolet irradiation for example.⁵

In a literature review, 35 cases of childhood-onset LCLE were identified, including our 2 cases (1978–2020, conducted through PubMed).^3,6–35 Median age of onset was 9 years old (1–17 years old), with a female predominance of 3F:1M. Different subtypes of CLE with a blaschkoid pattern have been described: discoid CLE (12 cases), lupus panniculitis (11), SCLE (1), bullous systemic lupus erythematosus (SLE) (1) and non-specified (10). The head and neck area were most frequently involved (57%), followed by extremities (46%) and trunk (14%), including 6 patients with multiple sites. LCLE lesions were usually erythematous and/or violaceous and may be atrophic (46%) and/or squamous (40%). Among patients with lupus panniculitis, 5 presented linear alopecia.^{8,22,27,28,30} Follicular plugging was noted in four cases (our case and previous studies),^14,29,35 sclerosis in three^13,19,35 and milia in one.²⁵ Patients were mostly asymptomatic but pruritis was occasionally noted.

The presence of SLE in LCLE is rare with only 2 patients reported.^15,31 The first patient had linear bullous SLE and suffered from fever, palpebral edema, malar rash, oral ulcers and arthritis.³¹ She had leucopenia and nephritis with positive ANA (1:1024), anti-dsDNA, anti-Ro and low complements (C3, C4). She responded well to systemic corticosteroids, hydroxychloroquine, and dapsone. The second patient had lupus panniculitis with fever, photosensitivity, oral ulcers, interstitial pneumonia, cytopenia and proteinuria.¹⁵ She had positive ANA (1:320), anti-Ro and anticoagulant autoantibodies (anti-dsDNA not disclosed). Complete remission was noted within 5 months of systemic corticosteroids and azathioprine. Four patients had isolated photosensitivity.^3,9,11,19

Among pediatric LCLE cases, the diagnosis was always confirmed by cutaneous biopsy. DIF positivity rate was 56% and showed linear and/or granular deposition of IgM +/- IgG, IgA and C3 deposition along dermoepidermal junction.^{3,6,8,18,20,23,31,33–35} ANA, anti-SSA/Ro and anti-dsDNA were positive in 33%^{3,6–8,11,15,17,18,26,27,31} (18% if ⩾1:160), 15%,^15,16,31 and 6%³¹ of cases, respectively. Full ENA panel was done in 8 cases (including our 2 patients), whereas other cases only disclosed about anti-SSA/Ro (mostly), anti-SSB/La, anti-Sm and/or anti-RNP. One patient had anti-histone autoantibodies without drug involvement.¹³ The only patient with anti-dsDNA autoantibodies had bullous SLE.³¹ Isolated leucopenia and isolated low complements were reported once.^3,8

Multiple treatments have been described with pediatric LCLE (Table 1).^{3,6–17,19–35} Remission rates were of 25% and 73% with topical treatments and systemic treatments (in monotherapy or combination), respectively. Among the latter group, 6 patients initially failed to respond to topical treatments. Systemic treatments were often in combination and included corticosteroids, antimalarials and dapsone with remission rates of 100%, 63% and 100%. Time to remission was not often specified, but a period of 3 to 5 months was described in children under systemic treatments. It is difficult to draw conclusions about LCLE treatments due to various therapies and disease severity in reported cases, but topical treatments seem generally insufficient requiring systemic treatments.

Table 1.

Treatments reported in the 35 pediatric cases of linear cutaneous lupus erythematosus.

Treatments	Total no.	Remission no. (%)	Improvement no. (%)	Failure no. (%)
Topical treatment	8	2 (25)	3 (38)	3 (38)
Corticosteroids^{7,17,27,29,32}	5	1 (20)	1 (20)	3 (60)
TCI²⁰	1	1 (100)	–	–
Corticosteroids and TCI^21,25	2	–	2 (100)	–
Systemic treatment	26	19 (73)	6 (23)	1 (4)
1. Systemic corticosteroids with	7	7 (100)	–	–
Topical corticosteroids^16,33	2	2 (100)	–	–
Antimalarial^a,22,30	2	2 (100)	–	–
MTX¹³	1	1 (100)	–	–
AZA^c,15	1	1 (100)	–	–
Antimalarial and dapsone^b,c,31	1	1 (100)	–	–
2. Antimalarial with	19	12 (63)	6 (32)	1 (5)
In monotherapy^10,11,23,26	4	3 (75)	1 (25)	–
Topical corticosteroids^{8,14,19,28,35}	5	4 (80)	1 (20)	–
TCI (our case and previous studies)³	4	–	4 (100)	–
Topical corticosteroids and TCI (our case and previous studies)³⁴	2	2 (100)	–	–
Topical corticosteroids, TCI, MTX and MMF⁹	1	–	–	1 (100)
Systemic corticosteroids^a,22,30	2	2 (100)	–	–
Systemic corticosteroids and dapsone^b,c,31	1	1 (100)	–	–
3. Dapsone with	4	4 (100)	–	–
In monotherapy⁶	1	1 (100)	–	–
Topical anti-inflammatory⁶	1	1 (100)	–	–
Topical corticosteroids¹²	1	1 (100)	–	–
Systemic corticosteroids and antimalarial^b,c,31	1	1 (100)	–	–

AZA: azathioprine; MMF: mycophenolate mofetil; MTX: methotrexate; TCI: topical calcineurin inhibitors; SLE: systemic lupus erythematosus.

Represents the same patient.

Patient with SLE.

LCLE was diagnosed in our 2 patients considering blaschkoid distribution of lesions and cutaneous biopsy’s results. Both improved significantly with a combination of hydroxychloroquine and topical corticosteroids or tacrolimus. Interestingly, our first patient didn’t respond to topical potent corticosteroids in monotherapy, as reported in some cases in the literature. In conclusion, LCLE is a rare presentation of CLE with mostly good prognosis which should be considered in children with Blaschko-linear squamous erythemato-violaceous lesions and may require systemic treatment.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

The patients provided written consent for publication of the case report.

ORCID iD

Darosa Lim

References

Dickey

Holland

Drolet

, et al. Demographic and clinical characteristics of cutaneous lupus erythematosus at a paediatric dermatology referral centre. Br J Dermatol 2013; 169(2): 428–433.

Lee

Baek

Roh

, et al. Clinical characteristics of pediatric cutaneous lupus erythematosus: experience from a tertiary referral center in Korea. Lupus 2019; 28(7): 888–892.

Jin

Zhang

Zhou

, et al. Old lines tell new tales: Blaschko linear lupus erythematosis. Autoimmun Rev 2016; 15(4): 291–306.

Molho-Pessach

Schaffer

JV.

Blaschko lines and other patterns of cutaneous mosaicism. Clin Dermatol 2011; 29(2): 205–225.

Seitz

Bröcker

Trautmann

Linear variant of chronic cutaneous lupus erythematosus: a clue for the pathogenesis of chronic cutaneous lupus erythematosus. Lupus 2008; 17(12): 1136–1139.

Abe

Ishikawa

Miyachi

Linear cutaneous lupus erythematosus following the lines of Blaschko. Br J Dermatol 1998; 139(2): 307–310.

Aiyama

Muro

Sugiura

, et al. Extraordinarily long linear cutaneous lupus erythematosus along the lines of Blaschko. Dermatol Online J 2013; 19(7): 18960.

Bacanli

Uzun

Ciftcioglu

, et al. A case of lupus erythematosus profundus with unusual manifestations. Lupus 2005; 14(5): 403–405.

Campos- Muñoz

Fueyo-Casado

Conde-Taboada

, et al. Clinical images: progressive linear blaschkoid lupus erythematosus. Arthritis Rheumatol 2017; 69(11): 2250.

10.

Choi

Chang

Choi

, et al. A linear erythema on the nose of a Korean girl. J Dermatol 2001; 28(2): 106–107.

11.

Daldon

Lage

Linear chronic discoid lupus erythematosus following the lines of Blaschko. An Bras Dermatol 2011; 86(3): 553–556.

12.

Davies

Newman

Linear cutaneous lupus erythematosus in association with ipsilateral submandibular myoepithelial sialadenitis. Clin Exp Dermatol 2001; 26(1): 56–58.

13.

Elbendary

Griffin

, et al. Linear sclerodermoid lupus erythematosus profundus in a Child. Am J Dermatopathol 2016; 38(12): 904–909.

14.

Engelman

Kotz

3rd Maize

, et al. Linear cutaneous lupus erythematosus in the lines of Blaschko. Pediatr Dermatol 2007; 24(2): 125–129.

15.

Fernandes

Santos

Freitas

, et al. Linear lupus erythematosus profundus as an initial manifestation of systemic lupus erythematosus in a child. Pediatr Dermatol 2014; 31(3): 378–380.

16.

Frances

Betlloch

Leiva-Salinas

, et al. Subacute cutaneous lupus erythematosus starting as linear lupus erythematosus. Int J Dermatol 2016; 55(2): 173–176.

17.

Green

Baker

DJ.

Linear childhood discoid lupus erythematosus following the lines of Blaschko: a case report with review of the linear manifestations of lupus erythematosus. Pediatr Dermatol 1999; 16(2): 128–133.

18.

Innocenzi

Pranteda

Giombini

, et al. Linear lupus erythematosus profundus in an adolescent. Eur J Dermatol 1997; 7(6): 445–447.

19.

Julià

Mascaró

Jr Guilabert

, et al. Sclerodermiform linear lupus erythematosus: a distinct entity or coexistence of two autoimmune diseases? J Am Acad Dermatol 2008; 58(4): 665–667.

20.

Kawachi

Taguchi

Fujisawa

, et al. Linear childhood discoid lupus erythematosus following the lines of Blaschko: successfully treated with topical tacrolimus. Pediatr Dermatol 2011; 28(2): 205–207.

21.

Kieselová

Santiago

Cunha

, et al. Unilateral erythematous linear lesions on the face of a 2-year-old infant. Pediatr Dermatol 2019; 36(3): e73–e74.

22.

Kshetrimayum

Thokchom

Hmar

Linear non scarring alopecia of the scalp: a rare manifestation of lupus panniculitis. Indian J Dermatol 2016; 61(5): 581.

23.

Lee

Choi

Sung

, et al. Linear cutaneous lupus erythematosus in the lines of Blaschko. Pediatr Dermatol 2001; 18(5): 396–399.

24.

Lueangarun

Subpayasarn

Tempark

Distinctive lupus panniculitis of scalp with linear alopecia along Blaschko’s lines: a review of the literature. Int J Dermatol 2019; 58(2): 144–150.

25.

Liao

Qiu

, et al. Linear cutaneous lupus erythematosus with calcinosis cutis and milia. Pediatr Dermatol 2015; 32(1): e33–e35.

26.

Marinho

Ramos

Barbosa

, et al. Linear cutaneous lupus erythematosus following the lines of Blaschko—case report. An Bras Dermatol 2016; 91(4): 510–513.

27.

Nagai

Ishikawa

Hattori

, et al. Linear lupus erythematosus profundus on the scalp following the lines of Blaschko. Eur J Dermatol 2003; 13(3): 294–296.

28.

Park

Kwak

Yun

, et al. Two annular alopecic lesions on the scalp in a young Asian man: a quiz. Acta Derm Venereol 2017; 97(3): 418–419.

29.

Requena

Torrelo

de Prada

, et al. Linear childhood cutaneous lupus erythematosus following Blaschko lines. J Eur Acad Dermatol Venereol 2002; 16(6): 618–620.

30.

Rhee

Kim

, et al. Two cases of linear alopecia on the occipital scalp. Ann Dermatol 2009; 21(2): 159–163.

31.

Roholt

Lapiere

Wang

, et al. Localized linear bullous eruption of systemic lupus erythematosus in a child. Pediatr Dermatol 1995; 12(2): 138–144.

32.

Tada

Arata

Katayama

Linear lupus erythematosus profundus in a child. J Am Acad Dermatol 1991; 24(5 Pt2)871-874.

33.

Tamiya

Sowa

Nakanishi

, et al. Linear lupus erythematosus profundus on the face, following the lines of Blaschko. Int J Dermatol 2010; 49(12): 1459–1461.

34.

Tijiu

Chu

Linear lupus erythematosus profundus: report of a case and review of the literature. Dermatologica Sinica 2004; 22(2): 221–226.

35.

Umbert

Winkelmann

RK.

Concurrent localized scleroderma and discoid lupus erythematosus cutaneous “mixed” or “overlap” syndrome. Arch Dermatol 1978; 114(10): 1473–1478.

Linear cutaneous lupus erythematosus in children—report of two cases and review of the literature: A case report

Abstract

Keywords

Introduction

Case report

Case 1

Case 2

Discussion

Footnotes

Declaration of conflicting interests

Funding

Informed consent

ORCID iD

References